TROXEVAZINE 300 mg x 50 capsules TEVA

Troxevasin from the pharmaceutical company Teva is used to relieve edema and symptoms associated with chronic venous insufficiency (fatigue, heaviness, swelling and pain and stiffness, numbness and tingling of the legs, "restless legs" together with elastic compression stockings, to relieve symptoms of hemorrhoids; in the complex treatment of lymphedema and diabetic retinopathy and varicose dermatitis, in the complex treatment of varicose ulcers. It is available in a package of 50 capsules.

Composition
 in 1 capsule:

Troxerutin
300 mg

Excipients: Magnesium stearate, Lactose monohydrate, Composition of the hard gelatin capsule: Colours (E110, E104), Titanium dioxide (E171). Gelatin.

 
Method of use: 
Chronic venous insufficiency and its complications; symptomatic treatment of hemorrhoids – 1 capsule 2 or 3 times a day depending on the severity of the symptoms. Relief of symptoms usually occurs within 2 weeks. Treatment is discontinued after complete resolution of symptoms and edema. If symptoms recur, treatment can be resumed. Diabetic retinopathy – 1,800 – 3,000 mg. Lymphedema – 3,000 mg daily. Pediatric population – Experience in children under 18 years of age is limited, therefore its use is not recommended in them. The capsules are taken during meals with a glass of water. Contraindications Hypersensitivity to the active substance or to any of the excipients. Special warnings and precautions for use This product is not effective in edema associated with liver, kidney and cardiovascular diseases. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. The dye E110 may cause allergic reactions. Interaction with other medicinal products and other forms of interaction No drug interactions have been established. Fertility, pregnancy and lactation There is no evidence of a negative effect of the product during pregnancy and lactation, but nevertheless the use of the product in the first trimester of pregnancy is not recommended. It is excreted in breast milk in minimal amounts, which are not known to lead to clinically significant effects in the newborn. Effects on the ability to drive and use machines Troxevasin does not affect the ability to drive and use machines. Adverse drug reactions The observed adverse reactions are distributed by frequency in accordance with the MedDRA guidelines as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), including isolated cases. Adverse reactions are rarely observed during treatment with troxerutin capsules: System organ classes Very rare Rare Immune system disorders anaphylactic shock, anaphylactoid reactions, hypersensitivity reactions Nervous system disorders dizziness, headache Vascular disorders enchymosis Gastrointestinal disorders stomach pain, stomach discomfort, dyspepsia, flatulence diarrhea Skin and subcutaneous tissue disorders rash, itching, urticaria General disorders and administration site effects fatigue Overdose No cases of overdose with the product have been observed. In case of taking very high doses or in case of serious adverse reactions, treatment with Troxevasin is discontinued and symptomatic therapy is prescribed. Special storage conditions Store below 25 degrees Celsius. Do not freeze. Read the manufacturer's instructions for use.